Seed Innovations Ltd

Investee Company Update: Little Green Pharma Ltd

RNS Number : 1428C
Seed Innovations Limited
18 February 2022

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

18 February 2022

SEED Innovations Limited ("SEED" or the "Company")

Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to note an announcement by its portfolio company, Little Green Pharma Ltd ('LGP').

SEED owns a holding of 7,324,796 ordinary shares in LGP representing 3.1% of LGP's issued share capital.

Alfredo Pascual, VP of Investment Analysis of SEED, commented: "We are delighted by our investee company Little Green Pharma performance in the most recent Italian government supply tender. This represents an entry into the Italian medical cannabis market, one of the largest in Europe, and positions them well for future possibly larger supply application processes in the country. LGP passing the strict government qualification requirements is another reflection of the high quality of medical cannabis flower that LGP are producing from its Danish facility.

"This is also an endorsement of LGP's European strategy, and with a growing presence on the continent we hope to hear more from LGP as they progress product pathways into other countries, including Greece and Poland where progress has been announced in recent months."

The announcement by Little Green Pharma Ltd is set out below without material changes or adjustments:



· LGP awarded Government tender for medicinal cannabis flower from its Danish Facility into Italy

· Italian Government tenders the sole route into Italian flower market, with tender quality standards some of the highest globally and LGP one of only two suppliers to bid for tender

· Award builds on Company's growing European market momentum as LGP joins small group of international cannabis producers qualified to supply cannabis flower medicines into Italy

· Tender award grants LGP access to Italian market with 60 million population and Total Addressable Market of A$10 billion

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce the award of an Italian Government tender to deliver a shipment of EU GMP medicinal cannabis flower from its Danish Facility into Italy.

The shipment value of ~€200,000 is not material, however with the award LGP has joined a small group of international cannabis producers qualified to supply cannabis flower medicines into Italy, positioning LGP strongly for future upcoming Italian Government tenders. Italy has a population of 60 million people and a Total Addressable Market estimated at ~A$10 billion.

Italian Government tenders impose some of the highest GMP product quality standards globally, with LGP one of only two suppliers bidding for the tender and with only Aurora having been successful in the past. The shipment will be of historic inventory acquired as part of LGP's purchase of its Danish Facility from Canopy Growth.

The Italian award builds on LGP's growing momentum in European and UK markets, with LGP now having supplied products into Germany, France, the UK and Denmark as it also continues to progress product registration pathways into Greece and Poland.


For further information on the Company please visit  or contact: 


Ed McDermott /

Lance de Jersey

SEED Innovations Ltd

Email:   [email protected]


James Biddle /Roland Cornish

Beaumont Cornish Limited,



Tel: +44 (0) 207 628 3396

Isabella Pierre /Damon Heath

Shard Capital Partners LLP


Tel: +44 (0)20 7186 9927

Catherine Leftley /Isabelle Morris

St Brides Partners Ltd,

Financial PR


Email: [email protected]




SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.